Journal article icon

Journal article

Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.

Abstract:

PURPOSE: Ras/Raf/mitogen-activated protein-extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK signaling is critical for tumor cell proliferation and survival. Selumetinib is a potent, selective, and orally available MEK1/2 inhibitor. In this study, we evaluated the therapeutic efficacy of selumetinib alone or with cediranib, an orally available potent inhibitor of all three VEGF receptor (VEGFR) tyrosine kinases, in murine orthotopic non-small cell lung carcinoma (NSCLC) models. EXP...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Expand authors...
Journal:
Clinical cancer research : an official journal of the American Association for Cancer Research
Volume:
18
Issue:
6
Pages:
1641-1654
Publication date:
2012-03-05
DOI:
EISSN:
1557-3265
ISSN:
1078-0432
URN:
uuid:10b68dd8-46bc-40b8-b9dc-dccc9ede10e8
Source identifiers:
315410
Local pid:
pubs:315410

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP